[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"notifications-list":3,"$f1bwbrvxqep0dn":5},{"data":4},[],{"data":6,"error":11},{"id":7,"documentId":8,"slug":9,"name":10,"medical_code":11,"short_description":12,"alternate_name":11,"disambiguating_description":11,"citations":13,"drugs":28,"specialties":33,"cover":11},910,"fndk6ntm2ki9n9y5t3kfa049","cytochrome-p450-2c19-inducers","Cytochrome P450 2C19 Inducers",null,"CYP2C19 is a cytochrome P450 monooxygenase that oxidises polyunsaturated fatty acids, inserting one atom of molecular oxygen into the substrate and reducing the second to water with two electrons supplied by NADPH through cytochrome P450 reductase. Drugs in this class induce it - UniProt records that this P450 can be induced to high levels in liver and other tissues by various foreign compounds, including drugs, pesticides and carcinogens - so a co-administered substrate of the pathway is cleared faster and its exposure falls. FDA grades that consequence and defines an inducer by it: strong and moderate index inducers decrease the AUC of sensitive substrates of a given metabolic pathway by at least 80 percent and by 50 to under 80 percent respectively. A drug belongs here because its recorded effect on CYP2C19 is induction, not inhibition; as MED-RT populates the class, its one member is mavacamten.",[14,20,24],{"claims":15,"source":16,"licence":17,"source_url":18,"retrieved_at":19},"CYP2C19 substrates (polyunsaturated fatty acids) and the monooxygenase mechanism - one oxygen atom inserted into the substrate, the second reduced to water, two electrons from NADPH via cytochrome P450 reductase; INDUCTION: that this P450 can be induced to high levels in liver and other tissues by various foreign compounds, including drugs, pesticides and carcinogens.","UniProtKB P33261","not stated on source page","https:\u002F\u002Frest.uniprot.org\u002Funiprotkb\u002FP33261.json","2026-09-19",{"claims":21,"source":22,"licence":17,"source_url":23,"retrieved_at":19},"'Strong and moderate index inducers are drugs that decrease the AUC of sensitive substrates of a given metabolic pathway by >=80 percent and >=50 to \u003C80 percent, respectively.' - the FDA definition of an inducer, stated as a fall in substrate exposure.","FDA, Drug Development and Drug Interactions | Table of Substrates, Inhibitors and Inducers","https:\u002F\u002Fwww.fda.gov\u002Fdrugs\u002Fdrug-interactions-labeling\u002Fdrug-development-and-drug-interactions-table-substrates-inhibitors-and-inducers",{"claims":25,"source":26,"licence":17,"source_url":27,"retrieved_at":19},"Class membership: mavacamten. Note: for this class the members are returned by the plain classMembers URL, and the rela=has_MoA form returns an empty object - the reverse of most classes in this file.","RxNav RxClass class members (MED-RT), classId N0000185607","https:\u002F\u002Frxnav.nlm.nih.gov\u002FREST\u002Frxclass\u002FclassMembers.json?classId=N0000185607&relaSource=MEDRT",[29],{"id":30,"documentId":31,"slug":32,"name":32,"active_ingredient":11,"dosage_form":11,"administration_route":11},1769,"axusfveu24u0fdfhtc89rtbm","phenytoin",[]]